CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ — Insilico Medicine (“Insilico” or the “Company”, HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 (“First Half of…
Source: prnewswire
Country: United States